← Leaderboards
Frederick Locke
H. Lee Moffitt Cancer Ctr & Res Inst
$1,743,048
Attributed
$3,587,545
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,587,545 · 2
By mechanism
R01$2,766,745 · 1
K23$820,800 · 1
Top collaborators
- Heather S.L. Jim5 shared
- Brent John Small5 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Heather S.l. Jim$14,608,363
- Thomas H. Brandon$14,530,397
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsFutureResponseInnovationBiologicalAdultFrequenciesBaseCancer PatientT-LymphocyteAutologousResourcesInvestigationCytokinePhenotypeSamplingAntigensCar T Cell TherapyCareerCareer DevelopmentCell AgingBackBortezomibCancer Center
Grant awards (10)
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$770,748
R01 · FY2025 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$160,118
R01 · FY2024 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$657,991
R01 · FY2023 · CA
Accelerated aging after chimeric antigen receptor T-cell therapy (CART): Leveraging a novel population of cancer survivors to elucidate mechanisms of dementia$470,597
R01 · FY2023 · CA
Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison$707,291
R01 · FY2022 · CA
Breaking immune tolerance to Survivin in Multiple Myeloma$164,160
K23 · FY2019 · CA · contact PI
Breaking immune tolerance to Survivin in Multiple Myeloma$164,160
K23 · FY2018 · CA · contact PI
Breaking immune tolerance to Survivin in Multiple Myeloma$164,160
K23 · FY2017 · CA · contact PI
Breaking immune tolerance to Survivin in Multiple Myeloma$164,160
K23 · FY2016 · CA · contact PI
Breaking immune tolerance to Survivin in Multiple Myeloma$164,160
K23 · FY2015 · CA · contact PI